Furthermore, we confirmed the primary motifs of BCLAF1-SPOP interaction, and we also identified BCLAF1 as a potential therapeutic target and the efficacy of ICB treatment could be increased in HCC with high expression of BLCAF1 in vitro. The gene discussed is SPOP; the disease is hepatocellular carcinoma.